Procurement of antiviral drugs has increased seven and a half times.
the Russian hospital in April spent on the purchase of medicines by 40% more than in March. It follows from the DSM Group, which acquainted “Izvestia”. First and foremost, growth is associated with the capacity supply of antiviral drugs, including those used against the symptoms COVID-19. The most expensive was the purchase of tools lopinavir+ritonavir, it is used to treat HIV but it has also been recommended for patients with the novel coronavirus. In addition, the physicians ordered twice encapreppart. In April the stock has not yet spent, analysts say, but the volume of purchases at the end of may-June will likely be above normal level.
In April, the hospital purchased medicines at 22.4 billion rubles. It’s 40% more than in March, when hospital procurement was estimated at 15.9 billion rubles, recorded analysts of DSM Group. When compared with April last year, a growth of 25% (in the fourth month 2019, the hospital purchased drugs almost 18 billion rubles).
In real terms the hospital purchases in April was 39 million packages. It is only 19% higher than the March figure (32.7 million packs). The difference may be due to purchasing the larger packs, a preference for more expensive drugs or a combination of these two factors. If we compare the purchase in real terms from April last year, when the hospital bought the 52.5 million packages of medicines, this year there is a decrease of 26%.
the First hospital bought nearly 7.5 times more (644%) than in March. Costs increased by 3.2 billion to 3.7 billion rubles. A significant proportion of this amount fell on the preparation — leader in procurement: lopinavir+ritonavir. This tool is used in therapy HIV but it has also been recommended for patients with the novel coronavirus.
In relation to April 2019, the costs increased by 56%, then spent nearly 519 million rubles.
as for drugs for the treatment of cancer, their purchasing has almost doubled (95%) to 5.6 billion rubles.
“news” sent a request to the Federal compulsory medical insurance Fund, from the funds which financed the purchase of medicines.
the Hospital was preparing stocks of drugs for the treatment of people infected with coronavirus and in anticipation of a large surge in the incidence significantly increased its purchases, noted in conversation with “News” the General Director DSM Group Sergey shuljak. It can be assumed that the drugs were purchased “with reserve” and were not rapidly depleted completely, he said. However, most likely, the results at least may and June purchases will still be higher than normal levelI, the expert has predicted.
quickly build up a stock of antiviral drugs have allowed a change in the system of public procurement. Since the spread of the novel coronavirus is one of an emergency is a force majeure event, explained the Ministry of Finance in late March.
to Make purchases that are necessary in connection with the distribution of COVID-19, it is possible from a single supplier, if the mode of increased readiness. Otherwise due long procedures there is a risk not to have time to prevent an emergency.
we Can assume that at the time of purchasing the majority of lopinavir+ritonavir was planned to be used for the treatment of patients with coronavirus, but it is unlikely he will now be applied only so, says head of the Department for the prevention and control of AIDS Central research Institute of epidemiology, Vadim Pokrovsky.
In the latest version of the provisional methodological recommendations of the Ministry of health for the prevention, diagnosis and treatment of new coronavirus infection lopinavir+ritonavir included in the list of drugs that can be used in therapy.
However, the document has a clause that the currently available data on results of its application (as well as favipiravir, of hydroxychloroquine, chloroquine, mefloquine, etc.) do not allow to make an unambiguous conclusion about the effectiveness or ineffectiveness. Therefore, the use of controversial drugs “allowed by the decision of the medical Commission in the prescribed manner if the potential benefit to the patient exceeds the risk of their use.”
the Capacity of incoprporated on the background of the pandemic may surprise you, however, it is absolutely justified, noted, in turn, former head of Federal Fund of obligatory medical insurance (FFOMS), Vladimir Grishin.
— Indeed, the planned treatment in almost all directions stopped, but cancer usually, we’re talking life and death. The capacity of the procurement can be associated with many factors. Including with the desire of the doctors to stock up while these already expensive drugs rose in price after the jump in the exchange rate, fears of disruptions in supplies due isolation, — said the expert.
As reported by “Izvestia”, some regions began to increase its purchases of antiviral drugs in February. Almost a third of all purchased in the country, drugs to relieve symptoms COVID-19 occurred in the hospital of the five most “Thrifty” subjects. Moscow (10.6% of purchases throughout the country), Moscow and Sverdlovsk region (6.5 and 5% respectively), St. Petersburg (4,6%) and Irkutsk oblast (3%).